Author Question: When instructing patients on the use of a volume-displacement incentive spirometer, the respira-tory ... (Read 63 times)

bb

  • Hero Member
  • *****
  • Posts: 544
When instructing patients on the use of a volume-displacement incentive spirometer, the respira-tory therapist should inform the patients to do which of the following?
 
  a. Inhale deeply and hold for 3 to 5 seconds.
  b. Exhale as fast as possible into the mouth-piece.
  c. Inhale and exhale rapidly through the mouthpiece.
  d. Perform 30 sustained maximum inspira-tions every 15 minutes.

Question 2

Untreated atelectasis can result in which of the following? 1. Decreased shunting 2. Increased shunting 3. Hypercapnia 4. Hypocapnia
 
  a. 1 and 3 c. 1 and 4
  b. 2 and 3 d. 2 and 4



AISCAMPING

  • Sr. Member
  • ****
  • Posts: 347
Answer to Question 1

ANS: A
After patients have achieved the maximum volume, they should be instructed to hold this volume constant for 3 to 5 seconds. The other choices are not techniques for use with incentive spirome-try.

Answer to Question 2

ANS: B
If atelectasis goes untreated, it can lead to pulmonary shunting, hypoxemia, hypercapnia, and ul-timately respiratory failure.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Chronic necrotizing aspergillosis has a slowly progressive process that, unlike invasive aspergillosis, does not spread to other organ systems or the blood vessels. It most often affects middle-aged and elderly individuals, spreading to surrounding tissue in the lungs. The disease often does not respond to conventionally successful treatments, and requires individualized therapies in order to keep it from becoming life-threatening.

Did you know?

In most cases, kidneys can recover from almost complete loss of function, such as in acute kidney (renal) failure.

Did you know?

The first war in which wide-scale use of anesthetics occurred was the Civil War, and 80% of all wounds were in the extremities.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

Drug-induced pharmacodynamic effects manifested in older adults include drug-induced renal toxicity, which can be a major factor when these adults are experiencing other kidney problems.

For a complete list of videos, visit our video library